Clinical Trial Update: A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and tolerability of pimavanserin (ACP-103) in Parkinson's disease psychosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Psychosis
• Parkinson Disease with Psychosis

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Parkinson's Disease Psychosis | Phase 3 | Status: COMPLETED | Results posted: 2019-06-24